Stockscreener 앱 받기
40.46
4.82%
-2.05
전일 마감가:
$42.51
열려 있는:
$41.06
하루 거래량:
456.22K
Relative Volume:
0.63
시가총액:
$1.45B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.34%
1개월 성능:
-12.06%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$40.38
$42.00
1주일 범위
$39.83
$47.98
52주 변동 폭
$14.72
$49.91
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
명칭
First Tracks Biotherapeutics Inc
전화
212-373-3000
주소
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
40.46 | 1.50B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | Leerink Partners | Outperform |
| 2026-04-24 | 개시 | Wedbush | Outperform |
| 2026-04-23 | 개시 | JP Morgan | Overweight |
| 2026-04-22 | 개시 | Barclays | Overweight |
| 2026-04-21 | 개시 | UBS | Buy |
First Tracks Biotherapeutics Inc 주식(TRAX)의 최신 뉴스
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65 - Moomoo
Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $95 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
First Tracks Biotherapeutics CBO Benjamin Stone Receives 60,492 Performance Stock Units - Kalkine Media
First Tracks Biotherapeutics' CMO Paul F. Lizzul Earns 60,492 Performance Stock Units Following Certified Milestones - Kalkine Media
First Tracks Biotherapeutics CEO Daniel Faga Awarded 193,575 Performance Stock Units - Kalkine Media
First Tracks (TRAX) insider records new share trades - Stock Titan
First Tracks Biotherapeutics (TRAX) insider updates holdings - Stock Titan
First Tracks Biotherapeutics (TRAX) insider logs trades - Stock Titan
Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX) - MarketBeat
Wolfe Research initiates First Tracks stock with outperform rating By Investing.com - Investing.com Canada
We're Hopeful That First Tracks Biotherapeutics (NASDAQ:TRAX) Will Use Its Cash Wisely - Sahm
FIRST TRACKS BIOTHERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $30 - Bitget
Why Did CRCL Stock Lose Steam? Wall Street Split On Circle’s Banking Win - Stocktwits
AnaptysBio earnings ahead: First results as royalty company By Investing.com - Investing.com Australia
AnaptysBio earnings ahead: First results as royalty company - Investing.com
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
TRAX SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics (NASDAQ: TRAX) Share Price, TRAX Stock News, TRAX Share Price & Updates - kalkine.ca
First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $63.38, Implies 37% Upside - TradingView
Piper Sandler raises First Tracks stock price target on pipeline progress - Investing.com Australia
TRAX Maintained by First Tracks -- Price Target Raised to $95.00 - GuruFocus
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results - Benzinga
A Quick Look at Today's Ratings for First Tracks Biotherapeutics(TRAX.US), With a Forecast Between $57 to $95 - Moomoo
TRAX Maintained by HC Wainwright & Co. -- Price Target Raised to $57.00 - GuruFocus
Wedbush Adjusts PT on First Tracks Biotherapeutics to $70 From $60, Maintains Outperform Rating - marketscreener.com
First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $60.5, Implies 31% Upside - tradingview.com
Barclays Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65 - Moomoo
TRAX SWOT Analysis: Clinical Pipeline and Financial Challenges R - GuruFocus
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:13 AM - Bitget
First Tracks Biotherapeutics Reports Q2 2026 Financial Results Following Spin-Off - Kalkine Media
Form 8K FIRST TRACKS BIOTHERAPEUTICS For: 12 August By Investing.com - Investing.com South Africa
First Tracks Biotherapeutics 2Q 2026: Net loss $(33.4M), EPS $(0.95) — 10-Q Summary - TradingView
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
First Tracks Biotherapeutics (TRAX) details $83.9M loss and $168M cash after spin-off - Stock Titan
FMR LLC Acquires Stake in First Tracks Biotherapeutics Inc (TRAX): A Strategic Bet on Clinical-Stage Innovation - GuruFocus
UBS Initiates First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Announces Target Price $65 - Moomoo
UBS Adjusts First Tracks Biotherapeutics PT to $65 From $45, Maintains Buy Rating - Moomoo
First Tracks Biotherapeutics (TRAX) reports 16,667 performance stock units - Stock Titan
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada
First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
First Tracks Biotherapeutics (TRAX) awards 60,492 performance stock units - Stock Titan
First Tracks Biotherapeutics (TRAX) awards 60,492 PSUs to CMO - Stock Titan
Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR - RTTNews
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo - The Globe and Mail
Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Wells Fargo Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential - TipRanks
After Forte acquisition, H.C. Wainwright says First Tracks could be target - TipRanks
TRAX Stock Volatile As Traders Focus On Cash And Momentum - StocksToTrade
First Tracks Biotherapeutics Inc (TRAX) 재무 분석
First Tracks Biotherapeutics Inc (TRAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
First Tracks Biotherapeutics Inc 주식 (TRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ware J. Anthony | Director |
Sep 02 '26 |
Sale |
44.78 |
39,265 |
1,758,145 |
15,660 |
0.86%
0.31%
자본화:
|
볼륨(24시간):